NCT03232346View on ClinicalTrials.gov

A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders

PHASE3CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Opioid-use Disorder
Interventions
DRUG

Vivitrol

Oral naltrexone induction procedure followed by Vivitrol

DRUG

Buprenorphine

5-week buprenorphine taper

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

New York State Psychiatric Institute

OTHER

NCT03232346 - A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders | Biotech Hunter | Biotech Hunter